Daiichi Sankyo Company, Limited (D4S.F)
| Previous close | 32.48 |
| Open | 31.79 |
| Bid | 32.47 x 50000 |
| Ask | 32.88 x 50000 |
| Day's range | 31.79 - 31.79 |
| 52-week range | 22.35 - 34.50 |
| Volume | |
| Avg. volume | 72 |
| Market cap | 61.845B |
| Beta (5Y monthly) | 0.25 |
| PE ratio (TTM) | 52.11 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.36 (1.12%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
- Business Wire
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
BASKING RIDGE, N.J. & RAHWAY, N.J., June 26, 2024--The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi Sankyo (TSE: 4568) and Merck’s (known as MSD outside of the United States and Canada) (NYSE: MRK) patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with tw
- Business Wire
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
TOKYO & BASKING RIDGE, N.J., June 02, 2024--ENHERTU Demonstrated a Median PFS of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow mBC Following One or More Lines of Endocrine Therapy
- PR Newswire
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody. The TIGIT component of rilvegostomig is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. Both rilvegostomi
